Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Clinical and Molecular Allergy

Fig. 4

From: Non-digestible oligosaccharides scFOS/lcFOS facilitate safe subcutaneous immunotherapy for peanut allergy

Fig. 4

Allergic manifestations evaluated in PE-sensitized mice after having received SCIT or SCIT in combination with scFOS/lcFOS. The effect of scFOS/lcFOS on the efficacy of SCIT, according to treatment protocol 2 (Fig. 1). a Change in body temperature after intraperitoneal challenge on day 77. b Anaphylactic shock symptom scores determined 40 min after intraperitoneal challenge on day 77. c Acute allergic skin response measured as Δ ear swelling 1 h after intradermal challenge on day 64. Δ Ear swelling was calculated as average of left and right ear swelling subtracted with the basal ear thickness before challenge. d Concentrations of MMCP-1 in serum collected 30 min after intragastric challenge on day 70. Data are represented as mean ± SEM n = 6–8 mice/group. Statistical analysis was performed using a two-way repeated measures ANOVA with Bonferroni’s post hoc test (body temperature) one-way ANOVA and Bonferroni’s post hoc test (acute allergic skin response and MMCP-1) or a Kruskal–Wallis test with Dunn’s post hoc test (Clinical score). ####P < 0.0001; ##P < 0.01 compared to sham-sensitized control. ****P < 0.0001; **P < 0.01; *P < 0.05 compared to PE-sensitized control. s.c., subcutaneous; PE, peanut extract; FF, scFOS/lcFOS; MMCP-1, mucosal mast cell protease-1; IT, immunotherapy

Back to article page